Insider Selling: Insmed Incorporated (NASDAQ:INSM) CFO Sells 1,579 Shares of Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) CFO Sara Bonstein sold 1,579 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $71.50, for a total transaction of $112,898.50. Following the transaction, the chief financial officer now owns 113,288 shares of the company's stock, valued at approximately $8,100,092. This represents a 1.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Sara Bonstein also recently made the following trade(s):

• On Wednesday, May 14th, Sara Bonstein sold 1,634 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total value of $107,206.74.
• On Tuesday, May 13th, Sara Bonstein sold 8,870 shares of Insmed stock. The shares were sold at an average price of $67.81, for a total value of $601,474.70.

Insmed Trading Up 0.9%

Insmed stock traded up $0.66 during trading hours on Friday, reaching $73.40. The stock had a trading volume of 631,076 shares, compared to its average volume of 2,071,260. Insmed Incorporated has a 52 week low of $55.74 and a 52 week high of $84.91. The stock has a market cap of $13.37 billion, a PE ratio of -13.12 and a beta of 0.80. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company has a fifty day simple moving average of $69.25 and a 200-day simple moving average of $73.03.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Insmed's revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.06) EPS. Analysts forecast that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Insmed

Hedge funds have recently made changes to their positions in the company. Darwin Global Management Ltd. lifted its position in Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after buying an additional 2,463,261 shares during the period. Norges Bank purchased a new stake in shares of Insmed in the 4th quarter worth about $126,606,000. Adage Capital Partners GP L.L.C. increased its stake in shares of Insmed by 109.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock worth $262,967,000 after acquiring an additional 1,799,382 shares in the last quarter. Nuveen LLC purchased a new position in Insmed during the 1st quarter valued at about $88,351,000. Finally, Vanguard Group Inc. lifted its position in Insmed by 6.3% during the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after acquiring an additional 1,075,796 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on INSM. Wells Fargo & Company lifted their price target on shares of Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 19th. Morgan Stanley lifted their price objective on Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Truist Financial raised their target price on shares of Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, UBS Group reduced their target price on shares of Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $96.73.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.